EIB provides EUR 400 million loan to Fresenius for R&D and EU manufacturing capacity expansion

Mechanism

The EIB, the EU's policy bank, financed Fresenius's pan-European R&D and capacity-expansion programme directly, following the same "EU policy bank loan to a European industrial champion" pattern as parallel EIB financings to Soitec (semiconductors) and Volvo (automotive/battery) filed from the same 2025-09 GTA batch. Fresenius Kabi's manufacturing footprint spans approximately 20 sites across Europe; the loan covers biosimilars, generics, infusion therapies and clinical-nutrition products plus the devices used to administer them. Both Fresenius (CFO Sara Hennicken) and the EIB frame the financing explicitly around supply-chain resilience and reducing reliance on non-EU pharmaceutical production — a "local-for-local" strategy consistent with the EU's broader push (alongside the Critical Medicines Act track) to re-shore essential-medicine manufacturing capacity.

Severity is set low (2/5, quant) given the moderate absolute size (EUR 400m) relative to flagship EU industrial-policy vehicles (Chips Act, IRA-scale awards), but it is a genuine state-backed capital subsidy reinforcing EU pharmaceutical production onshoring.

Downstream implications

• Adds to the 2025 wave of EIB "state loan" interventions to European

industrial champions across sectors (semiconductors, pharma, automotive), reinforcing the broader Western industrial-policy stack theme.

• Reinforces EU generic-drug and biosimilar manufacturing capacity

independent of Asian API/finished-dose suppliers — relevant to the pharmaceutical-supply-chain-security strand of EU industrial policy alongside the Critical Medicines Act.

Open questions

• Which specific Fresenius Kabi sites receive the capacity-expansion capex

(not itemised in the public press release).

• Whether this loan is a standalone tranche or the first of a multi-year EIB

financing relationship with Fresenius.